Cetrelimab (JNJ 63723283, JNJ 3283) is a human IgG4kappa mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-gamma, IL-2, TNF-alpha level and inhibits tumor growth in vivo[1].
Molecular Weight:
(144.76 kDa)
Purity:
99
CAS Number:
[2050478-92-5]
Target:
Interleukin Related,PD-1/PD-L1,TNF Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
